HRP20210294T1 - Postupci liječenja akutnog bubrežnog oštećenja - Google Patents
Postupci liječenja akutnog bubrežnog oštećenja Download PDFInfo
- Publication number
- HRP20210294T1 HRP20210294T1 HRP20210294TT HRP20210294T HRP20210294T1 HR P20210294 T1 HRP20210294 T1 HR P20210294T1 HR P20210294T T HRP20210294T T HR P20210294TT HR P20210294 T HRP20210294 T HR P20210294T HR P20210294 T1 HRP20210294 T1 HR P20210294T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- patient
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404390P | 2016-10-05 | 2016-10-05 | |
| EP17787773.5A EP3522880B1 (en) | 2016-10-05 | 2017-10-05 | Methods of treating acute kidney injury |
| PCT/US2017/055400 WO2018067857A1 (en) | 2016-10-05 | 2017-10-05 | Methods of treating acute kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210294T1 true HRP20210294T1 (hr) | 2021-04-16 |
Family
ID=60153507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210294TT HRP20210294T1 (hr) | 2016-10-05 | 2017-10-05 | Postupci liječenja akutnog bubrežnog oštećenja |
Country Status (33)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113004205B (zh) | 2015-10-07 | 2024-07-02 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
| ES2861503T3 (es) * | 2016-04-13 | 2021-10-06 | Mitobridge Inc | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
| JP7017563B2 (ja) | 2016-10-05 | 2022-02-08 | ミトブリッジ，インコーポレーテッド | Ｐｐａｒアゴニスト化合物の結晶性および塩形態 |
| JP7561180B2 (ja) | 2019-07-19 | 2024-10-03 | ヴィフォール （インターナショナル） アクチェンゲゼルシャフト | 腎臓損傷の予防及び治療で使用するためのフェロポーチン阻害剤 |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CN115813901B (zh) * | 2022-10-20 | 2024-10-22 | 南京市儿童医院 | 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2243766E (pt) | 2003-09-19 | 2015-10-20 | Janssen Pharmaceutica Nv | Ácidos 4-((fenoxialquil)tio)-fenoxiacéticos e análogos |
| MXPA06013581A (es) * | 2004-05-25 | 2007-03-15 | Metabolex Inc | Triazoles sustituidos como moduladores de ppar y metodos para su preparacion. |
| RU2320341C1 (ru) * | 2006-06-13 | 2008-03-27 | Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук | Средство для лечения острой обструкции верхних мочевыводящих путей |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| BRPI0920170A2 (pt) | 2008-10-17 | 2016-06-21 | Metabolex Inc | métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método. |
| US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| AU2014225320A1 (en) | 2013-03-08 | 2015-08-06 | Abbvie Inc. | Methods of treating acute kidney injury |
| CA2908695A1 (en) * | 2013-04-05 | 2014-10-09 | Salk Institute For Biological Studies | Ppar agonists |
| EP2862574A1 (en) | 2013-10-15 | 2015-04-22 | Sanofi | {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
| WO2015084939A1 (en) * | 2013-12-03 | 2015-06-11 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2016057658A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| WO2016057656A1 (en) | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases |
| CN113004205B (zh) * | 2015-10-07 | 2024-07-02 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
-
2017
- 2017-10-05 KR KR1020197012516A patent/KR20190062502A/ko not_active Ceased
- 2017-10-05 JP JP2019518278A patent/JP7065839B2/ja active Active
- 2017-10-05 AU AU2017340760A patent/AU2017340760B2/en active Active
- 2017-10-05 MD MDE20190903T patent/MD3522880T2/ro unknown
- 2017-10-05 SG SG11201901925RA patent/SG11201901925RA/en unknown
- 2017-10-05 RS RS20210203A patent/RS61573B1/sr unknown
- 2017-10-05 JO JOP/2019/0056A patent/JOP20190056B1/ar active
- 2017-10-05 EP EP17787773.5A patent/EP3522880B1/en active Active
- 2017-10-05 SM SM20210111T patent/SMT202100111T1/it unknown
- 2017-10-05 MY MYPI2019001558A patent/MY192385A/en unknown
- 2017-10-05 MX MX2019003949A patent/MX387518B/es unknown
- 2017-10-05 MA MA46459A patent/MA46459B1/fr unknown
- 2017-10-05 US US16/334,384 patent/US20210283116A1/en not_active Abandoned
- 2017-10-05 LT LTEP17787773.5T patent/LT3522880T/lt unknown
- 2017-10-05 CA CA3036723A patent/CA3036723A1/en active Pending
- 2017-10-05 DK DK17787773.5T patent/DK3522880T3/da active
- 2017-10-05 HU HUE17787773A patent/HUE053557T2/hu unknown
- 2017-10-05 RU RU2019111421A patent/RU2753607C2/ru active
- 2017-10-05 SI SI201730653T patent/SI3522880T1/sl unknown
- 2017-10-05 UA UAA201904011A patent/UA124019C2/uk unknown
- 2017-10-05 WO PCT/US2017/055400 patent/WO2018067857A1/en not_active Ceased
- 2017-10-05 TW TW106134387A patent/TWI778982B/zh active
- 2017-10-05 BR BR112019005539A patent/BR112019005539A2/pt not_active Application Discontinuation
- 2017-10-05 PL PL17787773T patent/PL3522880T3/pl unknown
- 2017-10-05 CN CN201780062021.8A patent/CN109789117B/zh active Active
- 2017-10-05 HR HRP20210294TT patent/HRP20210294T1/hr unknown
- 2017-10-05 ES ES17787773T patent/ES2859487T3/es active Active
- 2017-10-05 PT PT177877735T patent/PT3522880T/pt unknown
-
2019
- 2019-03-20 ZA ZA2019/01743A patent/ZA201901743B/en unknown
- 2019-04-01 IL IL265749A patent/IL265749A/en unknown
- 2019-04-03 PH PH12019500725A patent/PH12019500725A1/en unknown
- 2019-05-03 CO CONC2019/0004561A patent/CO2019004561A2/es unknown
-
2021
- 2021-02-23 CY CY20211100148T patent/CY1124759T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210294T1 (hr) | Postupci liječenja akutnog bubrežnog oštećenja | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2018513107A5 (enExample) | ||
| JP2015524444A5 (enExample) | ||
| WO2009127974A3 (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| RU2008152341A (ru) | Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| HRP20150375T1 (hr) | Derivati piridazinona | |
| RU2014120792A (ru) | Способ лечения стромальных опухолей желудочно-кишечного тракта | |
| JP2010518122A5 (enExample) | ||
| JP2012520866A5 (enExample) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2019533660A5 (enExample) | ||
| JP2013500977A5 (enExample) | ||
| JP2019517542A5 (enExample) | ||
| JP2020529995A5 (enExample) | ||
| JP2015522603A5 (enExample) | ||
| JP2006524699A5 (enExample) | ||
| HRP20191019T1 (hr) | Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2 | |
| JP2019529569A5 (enExample) | ||
| JP2011500650A5 (enExample) | ||
| BRPI0918593A2 (pt) | composição farmacêutica para uso no tratamento de infecções transmitidas sexualmente | |
| JP2008533079A5 (enExample) | ||
| JP2003246730A5 (enExample) | ||
| HRP20230634T1 (hr) | Pripravci za liječenje oftalmoloških stanja |